Literature DB >> 21262961

Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor.

Ruiwu Wang1, Xiaowei Zhong, Xing Meng, Andrea Koop, Xixi Tian, Peter P Jones, Bradley R Fruen, Terence Wagenknecht, Zheng Liu, S R Wayne Chen.   

Abstract

Dantrolene is believed to stabilize interdomain interactions between the NH2-terminal and central regions of ryanodine receptors by binding to the NH2-terminal residues 590-609 in skeletal ryanodine receptor (RyR1) and residues 601-620 in cardiac ryanodine receptor (RyR2). To gain further insight into the structural basis of dantrolene action, we have attempted to localize the dantrolene-binding sequence in RyR1/RyR2 by using GFP as a structural marker and three-dimensional cryo-EM. We inserted GFP into RyR2 after residues Arg-626 and Tyr-846 to generate GFP-RyR2 fusion proteins, RyR2Arg-626-GFP and RyR2Tyr-846-GFP. Insertion of GFP after residue Arg-626 abolished the binding of a bulky GST- or cyan fluorescent protein-tagged FKBP12.6 but not the binding of a smaller, nontagged FKBP12.6, suggesting that residue Arg-626 and the dantrolene-binding sequence are located near the FKBP12.6-binding site. Using cryo-EM, we have mapped the three-dimensional location of Tyr-846-GFP to domain 9, which is also adjacent to the FKBP12.6-binding site. To further map the three-dimensional location of the dantrolene-binding sequence, we generated 10 FRET pairs based on four known three-dimensional locations (FKBP12.6, Ser-437-GFP, Tyr-846-GFP, and Ser-2367-GFP). Based on the FRET efficiencies of these FRET pairs and the corresponding distance relationships, we mapped the three-dimensional location of Arg-626-GFP or -cyan fluorescent protein, hence the dantrolene-binding sequence, to domain 9 near the FKBP12.6-binding site but distant to the central region around residue Ser-2367. An allosteric mechanism by which dantrolene stabilizes interdomain interactions between the NH2-terminal and central regions is proposed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262961      PMCID: PMC3069424          DOI: 10.1074/jbc.M110.194316

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Localization of an NH(2)-terminal disease-causing mutation hot spot to the "clamp" region in the three-dimensional structure of the cardiac ryanodine receptor.

Authors:  Ruiwu Wang; Wenqian Chen; Shitian Cai; Jing Zhang; Jeff Bolstad; Terence Wagenknecht; Zheng Liu; S R Wayne Chen
Journal:  J Biol Chem       Date:  2007-04-23       Impact factor: 5.157

Review 2.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

3.  Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.

Authors:  Hitoshi Uchinoumi; Masafumi Yano; Takeshi Suetomi; Makoto Ono; Xiaojuan Xu; Hiroki Tateishi; Tetsuro Oda; Shinichi Okuda; Masahiro Doi; Shigeki Kobayashi; Takeshi Yamamoto; Yasuhiro Ikeda; Tomoko Ohkusa; Noriaki Ikemoto; Masunori Matsuzaki
Journal:  Circ Res       Date:  2010-03-11       Impact factor: 17.367

4.  Structural characterization of the RyR1-FKBP12 interaction.

Authors:  Montserrat Samsó; Xiaohua Shen; Paul D Allen
Journal:  J Mol Biol       Date:  2005-12-27       Impact factor: 5.469

Review 5.  Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies.

Authors:  Christopher H George; Hala Jundi; N Lowri Thomas; Debra L Fry; F Anthony Lai
Journal:  J Mol Cell Cardiol       Date:  2006-11-01       Impact factor: 5.000

6.  Localization of PKA phosphorylation site, Ser(2030), in the three-dimensional structure of cardiac ryanodine receptor.

Authors:  Peter P Jones; Xing Meng; Bailong Xiao; Shitian Cai; Jeff Bolstad; Terence Wagenknecht; Zheng Liu; S R Wayne Chen
Journal:  Biochem J       Date:  2008-03-01       Impact factor: 3.857

7.  Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.

Authors:  Gennady Cherednichenko; Chris W Ward; Wei Feng; Elaine Cabrales; Luke Michaelson; Montserrat Samso; José R López; Paul D Allen; Isaac N Pessah
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

8.  Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor.

Authors:  Xing Meng; Bailong Xiao; Shitian Cai; Xiaojun Huang; Fei Li; Jeff Bolstad; Ramon Trujillo; Judith Airey; S R Wayne Chen; Terence Wagenknecht; Zheng Liu
Journal:  J Biol Chem       Date:  2007-07-02       Impact factor: 5.157

9.  Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.

Authors:  Shigeki Kobayashi; Masafumi Yano; Takeshi Suetomi; Makoto Ono; Hiroki Tateishi; Mamoru Mochizuki; Xiaojuan Xu; Hitoshi Uchinoumi; Shinichi Okuda; Takeshi Yamamoto; Noritaka Koseki; Hiroyuki Kyushiki; Noriaki Ikemoto; Masunori Matsuzaki
Journal:  J Am Coll Cardiol       Date:  2009-05-26       Impact factor: 24.094

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more
  18 in total

1.  Dantrolene prevents arrhythmogenic Ca2+ release in heart failure.

Authors:  Joshua T Maxwell; Timothy L Domeier; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-16       Impact factor: 4.733

2.  Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.

Authors:  Benjamin Yuen; Simona Boncompagni; Wei Feng; Tianzhong Yang; Jose R Lopez; Klaus I Matthaei; Samuel R Goth; Feliciano Protasi; Clara Franzini-Armstrong; Paul D Allen; Isaac N Pessah
Journal:  FASEB J       Date:  2011-11-30       Impact factor: 5.191

3.  N-terminal and central segments of the type 1 ryanodine receptor mediate its interaction with FK506-binding proteins.

Authors:  Tanya Girgenrath; Mohana Mahalingam; Bengt Svensson; Florentin R Nitu; Razvan L Cornea; James D Fessenden
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

4.  Sarcolipin is a newly identified regulator of muscle-based thermogenesis in mammals.

Authors:  Naresh C Bal; Santosh K Maurya; Danesh H Sopariwala; Sanjaya K Sahoo; Subash C Gupta; Sana A Shaikh; Meghna Pant; Leslie A Rowland; Eric Bombardier; Sanjeewa A Goonasekera; A Russell Tupling; Jeffery D Molkentin; Muthu Periasamy
Journal:  Nat Med       Date:  2012-09-09       Impact factor: 53.440

5.  Modeling a ryanodine receptor N-terminal domain connecting the central vestibule and the corner clamp region.

Authors:  Li Zhu; Xiaowei Zhong; S R Wayne Chen; Nilesh Banavali; Zheng Liu
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

6.  Two potential calmodulin-binding sequences in the ryanodine receptor contribute to a mobile, intra-subunit calmodulin-binding domain.

Authors:  Xiaojun Huang; Ying Liu; Ruiwu Wang; Xiaowei Zhong; Yingjie Liu; Andrea Koop; S R Wayne Chen; Terence Wagenknecht; Zheng Liu
Journal:  J Cell Sci       Date:  2013-07-18       Impact factor: 5.285

7.  Dantrolene suppresses spontaneous Ca2+ release without altering excitation-contraction coupling in cardiomyocytes of aged mice.

Authors:  Timothy L Domeier; Cale J Roberts; Anne K Gibson; Laurin M Hanft; Kerry S McDonald; Steven S Segal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-18       Impact factor: 4.733

8.  Conformational dynamics inside amino-terminal disease hotspot of ryanodine receptor.

Authors:  Xiaowei Zhong; Ying Liu; Li Zhu; Xing Meng; Ruiwu Wang; Filip Van Petegem; Terence Wagenknecht; S R Wayne Chen; Zheng Liu
Journal:  Structure       Date:  2013-10-17       Impact factor: 5.006

Review 9.  Emerging pathways driving early synaptic pathology in Alzheimer's disease.

Authors:  Clark A Briggs; Shreaya Chakroborty; Grace E Stutzmann
Journal:  Biochem Biophys Res Commun       Date:  2016-09-20       Impact factor: 3.575

10.  Site-specific labeling of the type 1 ryanodine receptor using biarsenical fluorophores targeted to engineered tetracysteine motifs.

Authors:  James D Fessenden; Mohana Mahalingam
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.